HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023   Data from MAESTRO-NASH study revealed that HistoIndex’s technology identified larger percentage of patients who showed improvement after Resmetirom treatment, compared to manual semi-quantitative pathologist-reads Company and collaborators will present 14 accepted abstracts at EASL Congress 2023 Presentations reinforce […]

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH   SINGAPORE, June 15, 2023 – Recent findings from the TANDEM study (NCT03517540) in 193 patients with nonalcoholic steatohepatitis (NASH) reveal the use of HistoIndex’s Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging and Artificial Intelligence (AI)

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine   SINGAPORE, June 15, 2023 – HistoIndex has announced that its novel technology combining Second Harmonic Generation/Two-Photon Excitation (SHG/TPE) imaging with Artificial Intelligence (AI), in a post hoc analysis of the FLIGHT-FXR study (NCT02855164), enabled the detection of

HistoIndex embarks on partnership with VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases   Advancing ML/AI-based technology in the study of liver diseases by furthering strategic partnerships using a stain-free digital pathology system. SINGAPORE, April 10, 2023 – Virginia Commonwealth University’s Stravitz-Sanyal Institute for Liver Disease and Metabolic

Appointment of Dr. David John Jeans CBE as HistoIndex’s Non-Executive Chairman   SINGAPORE, Jan. 9, 2023 – The Board of Directors (the “Board”) of HistoIndex (the “Company”) would like to announce the following changes in appointments to the Board with effect from 6th December 2022: (1) Mr Sim Giok Lak’s decision to step down as Non-Executive Chairman of the

HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial   SINGAPORE, July 29, 2022 – HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with

HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials This is a first-of-its-kind international study initiated in 2019 by HistoIndex to examine artificial intelligence (AI)-based approaches that may provide a more reliable way to assess the range of injury recorded as “hepatocyte

HistoIndex and Galecto to Collaborate on Galecto’s Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology   SINGAPORE, Oct. 20, 2021 – HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis and cancer.

HistoIndex’s Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet’s NASH FASCINATE-2 Phase 2b Clinical Trial   Singapore, 18 August, 2021 – HistoIndex, a global leading artificial intelligence (AI) digital pathology provider, has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences. HistoIndex’s integrated suite of stain-free imaging with AI-based fully quantitative and

HistoIndex’s AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo   SINGAPORE, June 25, 2021 – HistoIndex’s Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of